8-K: BiomX Bolsters Phage Therapy Pipeline with Adaptive Phage Therapeutics Acquisition and $50 Million Financing

BiomX acquired Adaptive Phage Therapeutics, secured $50 million in funding, and is advancing its clinical-stage phage therapy programs for cystic fibrosis and diabetic foot osteomyelitis.

Summary

• BiomX reported its fourth quarter and full year 2023 financial results, highlighting the acquisition of Adaptive Phage Therapeutics (APT) and a concurrent $50 million financing.
• The acquisition of APT expands BiomX's pipeline to include two Phase 2 assets: BX004 for cystic fibrosis (CF) and BX211 for diabetic foot osteomyelitis (DFO).
• The $50 million private placement is expected to fund the company through key data readouts for BX004 in Q3 2025 and BX211 in Q1 2025.
• Patient recruitment is on track for the BX211 Phase 2 trial, with 32 of 45 patients enrolled.
• BX004 received Orphan Drug Designation from the FDA for treating chronic pulmonary infections in CF patients.
• A Phase 1b/2a trial of BX004 showed positive results, including a 14.3% conversion to negative sputum culture for P. aeruginosa in a subgroup of patients.
• The company paused development of BX005 for atopic dermatitis to focus on CF and DFO programs.
• BiomX's cash balance was $15.9 million as of December 31, 2023, but the $50 million financing and repayment of $10.4 million in debt have improved its financial position.
• Research and development expenses were $16.7 million for 2023, while general and administrative expenses were $8.7 million.
• The net loss for 2023 was $26.2 million, and net cash used in operating activities was $21.3 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in clinical trials and a successful capital raise, but there are some concerns about the company's financial position and the risk of not getting stockholder approval for the preferred stock conversion.

Positives

• The acquisition of Adaptive Phage Therapeutics significantly strengthens BiomX's pipeline with the addition of BX211.
• The $50 million financing provides crucial capital to advance clinical programs through key data readouts.
• Positive results from the BX004 Phase 1b/2a trial demonstrate the potential of phage therapy for CF.
• Orphan Drug Designation for BX004 could lead to faster regulatory approval and market exclusivity.
• Patient enrollment in the BX211 Phase 2 trial is progressing well.
• The company has sufficient cash to fund operations for at least 12 months.

Negatives

• The company's cash balance decreased from $34.3 million to $15.9 million in 2023.
• The company paused development of BX005 for atopic dermatitis.
• The financial statements contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The net loss for 2023 was $26.2 million.

Risks

• There is a risk that stockholders may not approve the conversion of the Convertible Preferred Stock issued as part of the APT acquisition.
• Clinical trial results may not replicate earlier findings.
• The company faces risks related to drug discovery, preclinical and clinical development, and regulatory approvals.
• There are uncertainties regarding the sufficiency of cash resources and the ability to manage unplanned cash requirements.
• The company is subject to competition and general economic and market conditions.

Future Outlook

The company expects to initiate a Phase 2b trial for BX004 in Q4 2024, with results expected in Q3 2025, and anticipates topline results from the BX211 Phase 2 trial in Q1 2025. The company believes its current cash is sufficient to fund operations for at least 12 months.

Management Comments

• Jonathan Solomon, Chief Executive Officer of BiomX, stated that the results from the BX004 trial take the company one step closer to bringing forward a new and effective phage-based treatment option for CF patients.
• The CEO also noted that the acquisition of Adaptive Phage Therapeutics provides BiomX with a second, exciting Phase 2 asset, BX211, for DFO.
• The concurrent $50 million financing provides the capital needed to reach important clinical milestones over the next 12-24 months.

Industry Context

The announcement positions BiomX as a leader in the emerging field of phage therapy, which offers a novel approach to treating bacterial infections, particularly those resistant to antibiotics. The acquisition of APT and the concurrent financing are significant steps in consolidating the company's position in this space.

Comparison to Industry Standards

• BiomX's focus on phage therapy aligns with a growing interest in alternative treatments for antibiotic-resistant infections, a major global health concern.
• The company's clinical trial progress for BX004 and BX211 is comparable to other biotech companies developing novel therapies for infectious diseases.
• The $50 million financing is a significant amount for a company at this stage, indicating strong investor confidence in the potential of phage therapy.
• Companies like Armata Pharmaceuticals and AmpliPhi Biosciences are also working on phage therapies, but BiomX's acquisition of APT and its focus on specific indications like CF and DFO set it apart.
• The positive results from the BX004 Phase 1b/2a trial are encouraging, but further data from Phase 2 trials will be crucial to assess its efficacy compared to existing treatments.

Stakeholder Impact

• Shareholders will benefit from the company's strengthened pipeline and improved financial position.
• Employees will continue to work on the development of novel phage therapies.
• Patients with CF and DFO may benefit from new treatment options.
• Creditors have been repaid with the $10.4 million debt repayment.

Next Steps

• Initiate a Phase 2b trial for BX004 in Q4 2024.
• Continue patient enrollment in the BX211 Phase 2 trial.
• Report topline results from the BX211 Phase 2 trial in Q1 2025.
• Report results from the Phase 2b trial of BX004 in Q3 2025.

Key Dates

Keywords

phage therapy, cystic fibrosis, diabetic foot osteomyelitis, BX004, BX211, clinical trial, FDA, Orphan Drug Designation, acquisition, financing